marcelsalathe
Fun fact: we have no clue how most drugs works. Or, more precisely, we know a few aspects, but are only scratching the surface. We're even still discovering news things about Aspirin, one of the oldest drugs: https://www.nature.com/articles/s41586-025-08626-7
This shift is more profound than many realize. Engineering traditionally applied our understanding of the physical world, mathematics, and logic to build predictable things. But now, especially in fields like AI, we’ve built systems so complex we no longer fully understand them. We must now use scientific methods - originally designed to understand nature - to comprehend our own engineered creations. Mindblowing.
https://engineeringprompts.substack.com/p/does-chatgpt-use-1...
“As CEO, I’m truly sorry to those impacted. But I strongly believe that this change is what is needed now to make sure Dropbox can thrive in the future.”
Making texts more accessible through clear language and well-structured arguments is a valuable service to the reader, and I applaud anyone who leverages LLMs to achieve that. I do the same myself.
GLM-4-9B: open-source model with superior performance to Llama-3-8B
Mistral AI co-founder and CTO: Frontier AI in your hands [video]
The development of medical interventions typically goes through a number of stages.
The earliest stage is called the pre-clinical phase, where a candidate intervention is tested outside of humans, either in vitro or in animals. The images of the mouse and ferret teeth suggest this has been done.
Phase 1 is when the intervention is first tested in humans, typically in small groups of usually dozens of participants. The aim here is not to evaluate efficacy - phase 1 studies are often too small for that - but to assess tolerability and safety, and to find the optimal dosing with respect to side effects.
If an intervention appears safe in certain doses, it can then be evaluated for initial efficacy and continued safety in a phase 2 trial, which is larger (usually hundreds of participants). Think of it as a kind of pilot trial to see if the intervention has the desired beneficial effects without serious negative side effects, and to identify the dose with the best benefit/risk ratio. About half of the studies get past this stage.
Those that do can enter phase 3, which is the full efficacy and safety assessment of the intervention. Again, about half of the phase 3 trials eventually make it to market. Of course, the intervention first needs to go to the health authorities for regulatory approval before it can be offered on the market.
For an interesting study on costs during these phases, see e.g. https://pubmed.ncbi.nlm.nih.gov/32125404/
I'm obviously very excited about medical progress but if we had a press conference for every planned phase 1 trial we wouldn't be doing much else ;-)